SciBac的封面图片
SciBac

SciBac

生物技术研究

Burlingame,California 291 位关注者

Always trust your gut

关于我们

SciBac creates rEvolutionary live biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. We improve beneficial microorganisms using our novel platform technology that can quickly, naturally, and safely transfer useful genetic traits. The resulting microorganism has all the best traits to target a specific disease through multiple modes of action and enhance the microbiome for faster recovery and reduced risk of reinfections. By focusing on developing therapies for antibiotic resistant diseases, SciBac fills a rapidly increasing medical need. SciBac’s first product targets the nation’s biggest antibiotic resistant threat, Clostridium difficile infection. Our microorganism strains out compete C. difficile by stopping colonization, neutralizing toxins, and directly killing the C. difficile organism. Unlike antibiotics, our product only targets C. difficile, allowing the rest of a patient’s microbiome to thrive, speeding up patient recovery and lowering the risk of recurrence.

网站
https://www.scibac.com
所属行业
生物技术研究
规模
2-10 人
总部
Burlingame,California
类型
私人持股
创立
2015

地点

  • 主要

    1828 El Camino Real

    US,California,Burlingame,94010

    获取路线

SciBac员工

相似主页

融资

SciBac 共 3 轮

上一轮

补助

US$286,530.00

Crunchbase 上查看更多信息